These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 17551835

  • 1. Bowman-Birk inhibitor concentrate: a novel therapeutic agent for patients with active ulcerative colitis.
    Lichtenstein GR, Deren JJ, Katz S, Lewis JD, Kennedy AR, Ware JH.
    Dig Dis Sci; 2008 Jan; 53(1):175-80. PubMed ID: 17551835
    [Abstract] [Full Text] [Related]

  • 2. Bowman-Birk inhibitor concentrate reduces colon inflammation in mice with dextran sulfate sodium-induced ulcerative colitis.
    Ware JH, Wan XS, Newberne P, Kennedy AR.
    Dig Dis Sci; 1999 May; 44(5):986-90. PubMed ID: 10235608
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial.
    Armstrong WB, Taylor TH, Kennedy AR, Melrose RJ, Messadi DV, Gu M, Le AD, Perloff M, Civantos F, Goodwin WJ, Wirth LJ, Kerr AR, Meyskens FL.
    Cancer Prev Res (Phila); 2013 May; 6(5):410-8. PubMed ID: 23639862
    [Abstract] [Full Text] [Related]

  • 5. Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment.
    Armstrong WB, Wan XS, Kennedy AR, Taylor TH, Meyskens FL.
    Laryngoscope; 2003 Oct; 113(10):1687-702. PubMed ID: 14520092
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia.
    Malkowicz SB, McKenna WG, Vaughn DJ, Wan XS, Propert KJ, Rockwell K, Marks SH, Wein AJ, Kennedy AR.
    Prostate; 2001 Jun 15; 48(1):16-28. PubMed ID: 11391683
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial.
    Gordon GL, Zakko S, Murthy U, Sedghi S, Pruitt R, Barrett AC, Bortey E, Paterson C, Forbes WP, Lichtenstein GR.
    J Clin Gastroenterol; 2016 Apr 15; 50(4):318-25. PubMed ID: 26368296
    [Abstract] [Full Text] [Related]

  • 13. Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia.
    Armstrong WB, Kennedy AR, Wan XS, Atiba J, McLaren CE, Meyskens FL.
    Cancer Epidemiol Biomarkers Prev; 2000 Jan 15; 9(1):43-7. PubMed ID: 10667462
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase I randomized double-blind placebo-controlled single-dose safety studies of Bowman-Birk inhibitor concentrate.
    Lin LL, Mick R, Ware J, Metz J, Lustig R, Vapiwala N, Rengan R, Kennedy AR.
    Oncol Lett; 2014 Apr 15; 7(4):1151-1158. PubMed ID: 24944684
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.